Advertisement

Topics

SignalRX Pharmaceuticals Awarded $2M Phase II STTR Grant From NCI For The Development Of Epigenetic-Kinase Inhibitors As Anticancer Agents

20:00 EDT 7 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: SignalRX Pharmaceuticals Awarded $2M Phase II STTR Grant From NCI For The Development Of Epigenetic-Kinase Inhibitors As Anticancer Agents

NEXT ARTICLE

More From BioPortfolio on "SignalRX Pharmaceuticals Awarded $2M Phase II STTR Grant From NCI For The Development Of Epigenetic-Kinase Inhibitors As Anticancer Agents"

Quick Search
Advertisement